Literature DB >> 31332060

In Vitro Synergy and In Vivo Activity of Tigecycline-Ciprofloxacin Combination Therapy against Vibrio vulnificus Sepsis.

Seong Eun Kim1, Hee Kyung Kim1,2, Su-Mi Choi1, Yohan Yu1, Uh Jin Kim1, Kalifa Sanneh Darboe1,2, Seung-Ji Kang1, Kyung-Hwa Park1, Gaeun Kang3, Young Ran Kim4, Joon Haeng Rhee5,6, Sook-In Jung7, Hee-Chang Jang7.   

Abstract

The mortality rate associated with Vibrio vulnificus sepsis remains high. An in vitro time-kill assay revealed synergism between tigecycline and ciprofloxacin. The survival rate was significantly higher in mice treated with tigecycline plus ciprofloxacin than in mice treated with cefotaxime plus minocycline. Thus, combination treatment with tigecycline-ciprofloxacin may be an effective novel antibiotic regimen for V. vulnificus sepsis.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  V. vulnificuszzm321990; sepsis; tigecycline

Year:  2019        PMID： 31332060      PMCID： PMC6761547          DOI： 10.1128/AAC.00310-19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  21 in total

1.  The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data.

Authors:  Timothy Babinchak; Evelyn Ellis-Grosse; Nathalie Dartois; Gilbert M Rose; Evan Loh
Journal:  Clin Infect Dis       Date:  2005-09-01       Impact factor: 9.079

2.  The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam.

Authors:  E J Ellis-Grosse; T Babinchak; N Dartois; G Rose; E Loh
Journal:  Clin Infect Dis       Date:  2005-09-01       Impact factor: 9.079

3.  Quantitative PCR and in vivo efficacy of antibiotics in the treatment of Vibrio vulnificus infection in a mouse model.

Authors:  G P Neupane; D-M Kim; N R Yun; S-H Shin; S-C Lim; C-H Choi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-03-21       Impact factor: 3.267

4.  In vitro efficacy of the combination of ciprofloxacin and cefotaxime against Vibrio vulnificus.

Authors:  Dong-Min Kim; Yong Lym; Sook Jin Jang; Hulin Han; Young Gi Kim; Choon-Hae Chung; Soon Pyo Hong
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

5.  The epidemiology of Vibrio infections in Florida, 1981-1993.

Authors:  W G Hlady; K C Klontz
Journal:  J Infect Dis       Date:  1996-05       Impact factor: 5.226

6.  The pyrH gene of Vibrio vulnificus is an essential in vivo survival factor.

Authors:  Shee Eun Lee; Soo Young Kim; Choon Mee Kim; Mi-Kwang Kim; Young Ran Kim; Kwangjoon Jeong; Hwa-Ja Ryu; Youn Suhk Lee; Sun Sik Chung; Hyon E Choy; Joon Haeng Rhee
Journal:  Infect Immun       Date:  2007-03-19       Impact factor: 3.441

7.  In vitro synergism between cefotaxime and minocycline against Vibrio vulnificus.

Authors:  Y C Chuang; J W Liu; W C Ko; K Y Lin; J J Wu; K Y Huang
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

8.  Minocycline and cefotaxime in the treatment of experimental murine Vibrio vulnificus infection.

Authors:  Y C Chuang; W C Ko; S T Wang; J W Liu; C F Kuo; J J Wu; K Y Huang
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

9.  Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model.

Authors:  Pornpan Koomanachai; Aryun Kim; David P Nicolau
Journal:  J Antimicrob Chemother       Date:  2009-03-11       Impact factor: 5.790

10.  In vivo efficacy of the combination of ciprofloxacin and cefotaxime against Vibrio vulnificus sepsis.

Authors:  Hee-Chang Jang; Su-Mi Choi; Hee Kyung Kim; Sung-Eun Kim; Seung-Ji Kang; Kyung-Hwa Park; Phil Youl Ryu; Tae-Hoon Lee; Young Ran Kim; Joon Haeng Rhee; Sook-In Jung; Hyon E Choy
Journal:  PLoS One       Date:  2014-06-30       Impact factor: 3.240
View more
  2 in total

1.  Antimicrobial Effects of Minocycline, Tigecycline, Ciprofloxacin, and Levofloxacin against Elizabethkingia anophelis Using In Vitro Time-Kill Assays and In Vivo Zebrafish Animal Models.

Authors:  Jiun-Nong Lin; Chung-Hsu Lai; Yi-Han Huang; Chih-Hui Yang
Journal:  Antibiotics (Basel)       Date:  2021-03-10

2.  Enhanced Biosynthesis of Fatty Acids Is Associated with the Acquisition of Ciprofloxacin Resistance in Edwardsiella tarda.

Authors:  Yu-Bin Su; Su-Fang Kuang; Jin-Zhou Ye; Jian-Jun Tao; Hui Li; Xuan-Xian Peng; Bo Peng
Journal:  mSystems       Date:  2021-08-24       Impact factor: 6.496
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.